Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Phase 2

Completed

Conditions: Hodgkin´s Lymphoma

First Posted Date: 2006-01-31

Last Posted Date: 2011-07-29

Lead Sponsor: University of Cologne

Target Recruit Count: 65

Registration Number: NCT00284271

Locations: 🇩🇪
University of Cologne, Cologne, Germany

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Phase 1

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Biological: Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Campath 1H
Drug: GCSF
Drug: Cyclosporins
Drug: Mycophenolate Mofetil

First Posted Date: 2006-01-26

Last Posted Date: 2018-07-30

Lead Sponsor: Northwestern University

Target Recruit Count: 4

Registration Number: NCT00282412

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors

Phase 2

Conditions: Brain and Central Nervous System Tumors
Neuroblastoma

First Posted Date: 2006-01-25

Last Posted Date: 2013-09-20

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 50

Registration Number: NCT00281905

Locations: 🇮🇪
Our Lady's Hospital for Sick Children, Dublin, Ireland
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom

and more 17 locations

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2006-01-25

Last Posted Date: 2013-09-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 817

Registration Number: NCT00281918

Locations: 🇩🇪
Praxis Fur Hamatologie und Onkologie Ahaus, Ahaus, Germany
🇩🇪
Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg, Augsburg, Germany
🇩🇪
Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany

and more 157 locations

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Phase 2

Terminated

Conditions: Prolymphocytic Leukemia

First Posted Date: 2006-01-25

Last Posted Date: 2016-09-26

Lead Sponsor: German CLL Study Group

Target Recruit Count: 21

Registration Number: NCT00281931

Locations: 🇩🇪
Helios Klinikum Erfurt, Erfurt, Germany

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Phase 2

Terminated

Conditions: Unusual Cancers of Childhood
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Drug: carmustine
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: cytarabine
Drug: mycophenolate mofetil
Drug: etoposide
Drug: methylprednisolone
Drug: tacrolimus
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 200

Registration Number: NCT00281879

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: alemtuzumab
Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: rituximab
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-01-25

Last Posted Date: 2017-07-24

Lead Sponsor: German CLL Study Group

Target Recruit Count: 100

Registration Number: NCT00281983

Locations: 🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
University Hospital of Leipzig, Leipzig, Germany
🇩🇪
Klinikum der Universitaet Regensburg, Regensburg, Germany

and more 10 locations

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2006-01-20

Last Posted Date: 2016-02-04

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 65

Registration Number: NCT00280241

Locations: 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: Pegfilgrastim
Biological: Rituximab
Drug: Cyclophosphamide

First Posted Date: 2006-01-18

Last Posted Date: 2018-11-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 94

Registration Number: NCT00278161

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Phase 1

Terminated

Conditions: MYOPATHY

Interventions: Biological: Hematopoietic stem cell transplantation
Drug: Cyclophosphamide
Drug: Mesna
Drug: ATG(rabbit)
Drug: Methylprednisolone
Drug: G-CSF
Drug: Rituxan

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-06

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT00278564

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy